Laboratory operations note: infection-control-is-a-procurement-problem-here039s-how-to-evaluate-it-like-172

Infection Control Is a Procurement Problem. Here's How to Evaluate It Like One.

I've coordinated emergency medical device orders for hospitals for close to nine years now. Long enough to spot the patterns. And the pattern I keep coming back to is this: infection control failures rarely start in the hospital room. They start in the purchasing requisition.

That's not a popular opinion in procurement circles. Most teams treat infection control as a clinical compliance item (nobody disagrees that it's important, but someone else owns it). Handwashing audits. Sterilization logs. Competency check-offs. And yes, those matter.

But I've lost count of how many rush orders I've filled because a device was hard to clean, a connector wasn't seamless, or a product hadn't been evaluated for infection risk before the contract was signed. When you're paying triple for next-day air freight because a pump failed environmental services inspection, that's not a clinical problem anymore. That's a procurement one.

The syringe pump problem nobody wants to talk about

Let's start with something concrete. In March 2024, I handled a rush request from a 340-bed hospital in the upper Midwest. They needed 12 replacement syringe pumps air-freighted within 72 hours because their existing units were failing infection control rounds.

The issue? The pump housing had recessed seams and a corrugated surface design that wasn't rated for the bleach-based disinfectants their environmental services team was using. The hospital had standardized on that model four years earlier, in a different clinical environment with different cleanliness protocols. Nobody had re-evaluated the device when protocols changed.

Normal lead time on those replacement pumps would've been 10-14 business days. We paid about $4,800 in expedited freight and surcharges to get them there in three. The hospital's alternative was to take beds offline for a week (not acceptable during respiratory season).

Here's the uncomfortable truth: that $4,800 was a procurement decision. The clinical team didn't buy the wrong pump. The procurement team did—without asking whether the device would support evolving disinfection protocols three years later.

When I look at infusion pump evaluations now (Smiths Medical's line, as an example, since we carry their syringe pump catalog), I mentally run a simple checklist: Are there seams? Can a disinfectant wipe get into every crevice? Has the manufacturer published cleaning validation data for the disinfectants my client actually uses? These aren't clinical questions. They're sourcing questions.

The incontinence product blind spot

Here's where I think the industry has a genuine blind spot—and where the change in infection control philosophy has been most dramatic over the past five years.

Incontinence products are almost never purchased with infection control as a primary criterion. They're bought on absorbency, fit, skin health (sometimes), and cost. Infection risk rarely makes the top three.

That's a mistake, and I think it's a legacy of how we've been taught to think about infection control: as an acute-care problem. Catheters, surgical sites, ventilators. But what is infection control if not the reduction of pathogen transmission in every patient-care interaction—including the ones that happen 20 times a day?

Research from the CDC and infection prevention societies has consistently shown that moisture-associated skin damage (MASD) is a risk factor for secondary infection. That's the medical framing. The procurement framing is simpler: if the product doesn't wick moisture away from skin effectively, you're creating the conditions for a problem.

I've had two conversations this past year with hospital supply chain managers who told me they'd switched incontinence suppliers after an infection control nurse flagged a correlation between product usage and perineal dermatitis rates. Neither of them had infection control on the evaluation scorecard originally. Both added it after the fact.

I don't have hard data on how many hospitals include MASD risk in their incontinence product scoring criteria. I wish I did—I've looked, and the published benchmarks are thin. What I can tell you anecdotally is that when I ask supply chain folks on the phone, most of them say "not formally" or "we probably should."

The ultrasound machine gap (and why Minnesota matters more than you'd think)

Ultrasound probe hygiene is another area where procurement decisions get ahead of clinical awareness. This one goes way beyond the reprocessing requirements you see in high-level disinfection guidelines for intracavity probes.

Surface probes are lower-risk, but not zero-risk—particularly in EDs and ICUs where the same machine moves between a wound check and a central line placement in the span of 20 minutes. A 2023 study in Infection Control & Hospital Epidemiology found that surface probe contamination rates after routine cleaning were higher than expected in high-turnover environments. I'm paraphrasing from memory, but the takeaway stuck: the cleaning step is often rushed, and the device design determines how easy it is to rush correctly.

This is where the Smiths Medical Minnesota connection is worth noting—not because Smiths Medical manufactures ultrasounds (they don't, as far as I know), but because the Medical Alley corridor in Minnesota has become a testing ground for device-cleaning validation methods. If you're sourcing equipment in that region, you have access to contract sterilization and validation services that most other regions don't. Use them. Ask your rep for the cleaning validation reports before you sign.

That's the kind of due diligence that doesn't show up on a standard RFP form.

"What was considered adequate interim cleaning in 2019 may not pass muster in 2025. The fundamentals haven't changed—pathogens still need moisture, a portal, and a host—but the execution expectations have shifted dramatically."

"But we follow the CDC guidelines"

I hear this a lot. And it's true—most of the hospitals I work with are compliant with current guidance. That's the floor, not the ceiling.

The CDC guidelines tell you what to do. They don't tell you which device makes it easy to do consistently. That's your job.

Looking back at the pump situation from March 2024, I should have pushed harder when the hospital's clinical engineering team asked me to expedite the order. At the time, I just saw a speed problem. It wasn't until six months later, when I ran into their IP director at a conference, that I understood it was a procurement problem that had been sitting dormant for years.

Even after I connected those dots, I kept second-guessing myself. Was I overstepping? Procurement teams don't usually want unsolicited advice from their suppliers about their evaluation criteria. But the more I looked at my order history—the devices we rush-ship because they fail environmental services inspection, the replacement requests that come in waves after flu season—the more I became convinced that infection control is as much a sourcing function as it is a clinical one.

Where that leaves you

The principles of infection control haven't changed. Clean equipment. Clean hands. Clean environment. But the execution has transformed, and the procurement decisions that support (or undermine) that execution now carry more weight than they did a decade ago.

If you're a supply chain lead reading this: add infection control as an evaluation criterion. Not as a checkbox—as a weighted category. Ask for cleaning validation data. Ask about seams and surface materials. Ask whether the device has been evaluated against the disinfectants your EVS team actually uses, not the ones in the brochure.

And if you're on the clinical side? Talk to procurement earlier. The device you're using today was chosen 18 months ago by someone who probably didn't have your infection control background. That's not their fault—it's a process gap. But it's a gap worth closing.

The alternative is more emergency calls. And I can tell you from experience: those get expensive.